Algorithms and Methods for Evaluating Late Clinical Endpoints in Prostate Cancer

摘要

The present disclosure provides a plurality of genes for assessing the risk of various clinical endpoints, such as clinical recurrence (CR), biochemical recurrence (BCR), distant metastasis (Mets) and prostate cancer death (PCD) in prostate cancer patients. It relates to the use of expression-based genomic prostate score ™ (GPS ™) algorithms. In some embodiments, GPS results are determined for those patients to help determine treatment strategies for low and medium risk prostate cancer patients.